Department of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Food Technology, Faculty of Nutrition and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Eur J Nutr. 2020 Aug;59(5):2111-2117. doi: 10.1007/s00394-019-02060-y. Epub 2019 Jul 20.
The aim of this study was to assess the superiority of low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs) diet plus Bacillus coagulans supplementation to low FODMAP diet alone in the reduction of irritable bowel syndrome (IBS) symptoms.
In this randomized clinical trial, fifty IBS patients who met Rome IV criteria for IBS were randomly assigned to receive a low FODMAP diet plus either a probiotic or a placebo capsule for 8 weeks. Probiotic capsules contained 10B. coagulans spores and 400 mg inulin, while placebo capsules consisted of 500 mg rice starch.
Significant improvements were observed in abdominal pain intensity and frequency, abdominal distension, satisfaction with bowel habits, quality of life, defecation consistency, and patient-reported severity score in both groups; however, only improvement in severity score was significantly higher in probiotic group compared with placebo group (P = 0.001). Moreover, the frequency of patients with clinical improvement in IBS-symptom severity scale (IBS-SSS) was significantly more in probiotic group compared to placebo group (P = 0.038).
Our results indicate that the addition of probiotic supplement containing B. coagulans to the low FODMAP diet might be superior to low FODMAP diet in alleviating IBS symptoms.
本研究旨在评估低发酵寡糖、双糖、单糖和多元醇（FODMAP）饮食联合凝结芽孢杆菌补充剂与单纯低 FODMAP 饮食相比在减轻肠易激综合征（IBS）症状方面的优越性。
在这项随机临床试验中，50 名符合罗马 IV 标准的 IBS 患者被随机分配接受低 FODMAP 饮食加益生菌或安慰剂胶囊治疗 8 周。益生菌胶囊含有 10B. coagulans 孢子和 400mg 菊粉，而安慰剂胶囊则由 500mg 米粉组成。
两组患者的腹痛强度和频率、腹胀、排便习惯满意度、生活质量、排便一致性和患者报告的严重程度评分均显著改善；然而，只有益生菌组的严重程度评分改善显著高于安慰剂组（P=0.001）。此外，益生菌组患者在 IBS 症状严重程度量表（IBS-SSS）上的临床改善频率显著高于安慰剂组（P=0.038）。
我们的结果表明，在低 FODMAP 饮食中添加含有凝结芽孢杆菌的益生菌补充剂可能优于低 FODMAP 饮食，可缓解 IBS 症状。
